Thyroid hormone augmentation in treatment-refractory depression

Clinical Psychopharmacology and Neuroscience

Volumn 6, Issue 1, 2008, Pages 3-10

  Obrocea, Gabriela V ^a,b   Margolin, Richard A ^a   Yoo, Tai P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KERN MEDICAL CENTER   (United States)

Author keywords

Levothyroxine; Thiiodothyronine; Thyroid; Thyroxine; Treatment refractory depression

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; DULOXETINE; FLUOXETINE; IMIPRAMINE; LIOTHYRONINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PINDOLOL; PLACEBO; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; THYRONINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADD ON THERAPY; BIPOLAR DEPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; MEDLINE; MOOD DISORDER; NONHUMAN; PATHOPHYSIOLOGY; RAPID CYCLING BIPOLAR DISORDER; REVIEW; SEX DIFFERENCE; THYROID DISEASE; THYROID FUNCTION; THYROTOXICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 40349089727     PISSN: 17381088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry 2003;53:640-648.
2. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000;61 (Suppl 1):26-32.
3. Post RM, Leverich GS, Denicoff KD, Frye MA, Kimbrell TA, Dunn R. Alternative approaches to refractory depression in bipolar illness. Depress Anxiety 1997;5:175-189.
4. Prange AJ Jr, Loosen PT. Hormone therapy in depressive diseases. Adv Biochem Psychopharmacol 1982;32:289-296.
5. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990; 51 (Suppl):39-47.
6. Nolen W, Zohar J, Roose S, Amsterdam J. Refractory Depression: Current Strategies and Future Directions, J. Wiley and Sons: Chichester; 1994.
7. O'Reardon JP, Brunswick DJ, Amsterdam JD. Treatment-resistant depression in the age of serotonin: evolving strategies. Curr Opin Psychiatry 2000;13:93-98
8. Fawcett J, Kravitz HM. Treatment of refractory depression. In: Schatzberg AF, editor. Common Treatment Problems in Depression. American Psychiatric Press: Washington DC; 1985. p.2-27.
9. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-132.
10. Thase M, Rush AJ. Treatment-resistant depression. In: Bloom F, Kupfer D, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995. p.1081-1098.
11. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9:83-91.
12. Kennedy SH, Joffe RT. Pharmacological management of refractory depression. Can J Psychiatry 1989;34:451-456.
13. Phillips KA, Nierenberg AA. The assessment and treatment of refractory depression. J Clin Psychiatry 1994;55 (Suppl):20-26.
14. Akiskal HS. Dysthymic and cyclothymic depressions: therapeutic considerations. J Clin Psychiatry 1994;55 (Suppl):46-52.
15. Kilzieh N, Akiskal HS. Rapid-cycling bipolar disorder. An overview of research and clinical experience. Psychiatr Clin North Am 1999;22:585-607.
16. Sussman N. Anxiolytic antidepressant augmentation. J Clin Psychiatry 1998;59 (Suppl 5):42-48.
17. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry 2003;64 (Suppl 1):5-12.
18. Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry 1998;59 (Suppl 5):60-63.
19. Amsterdam J. Refractory Depression, in Advances in Neuropsychiatry and Psychopharmacology (Vol. 2). New York: Raven Press; 1991.
20. Agid O, Lerer B. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int J Neuropsychopharmacol 2003;6:41-49.
21. Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999;60: 142-156.
22. Pridmore S, Turnier-Shea Y. Medication options in the treatment of treatment-resistant depression. Aust N Z J Psychiatry 2004;38:219-225.
23. Sussman N, Joffe RT. Antidepressant augmentation: conclusions and recommendations. J Clin Psychiatry 1998;59 (Suppl 5): 70-73.
24. Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61:669-680.
25. Grunze H, Marcuse A, Scharer LO, Born C, Walden J. Nefazodone in psychotic unipolar and bipolar depression: a retrospective chart analysis and open prospective study on its efficacy and safety versus combined treatment with amitriptyline and haloperidol. Neuropsychobiology 2002;46 (Suppl 1):31-35.
26. Shelton RC. The use of antidepressants in novel combination therapies. J Clin Psychiatry 2003;64 (Suppl 2):14-18.
27. Post RM, Frye MA, Denicoff KD, Leverich GS, Kimbrell TA, Dunn RT. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology 1998;19:206-219.
28. Bocchetta A, Chillotti C, Severino G, Ardau R, Del Zompo M. Carbamazepine augmentation in lithium-refractory bipolar patients: a prospective study on long-term prophlyactic effectiveness. J Clin Psychopharmacol 1997;17:92-96.
29. Dietrich DE, Emrich HM. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 1998;59 (Suppl 5): 51-58.
30. Simpson HB, Hurowitz GI, Liebowitz MR. General principles in the pharmacotherapy of antidepressant-induced rapid cycling: a case series. J Clin Psychopharmacol 1997;17:460-466.
31. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 1998;59 (Suppl 5):16-23.
32. Altshuler LL, Frye MA, Gitlin MJ. Acceleration and augmentation strategies for treating bipolar depression. Biol Psychiatry 2003;53:691-700.
33. Bauer M. Thyroid hormone augmentation with levothyroxine in bipolar depression. Bipolar Disord 2002;4 (Suppl 1):109-110.
34. Bauer M, Baur H, Berghofer A, Strohle A, Hellweg R, Muller-Oerlinghausen B, et al. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. J Affect Disord 2002;68:285-294.
35. Browne JL, Rice JL, Evans DL, Prange AJ. Triiodothyronine augmentation of the antidepressant effect of the nontricyclic antidepressant trazodone. J Nerv Ment Dis 1990;178:598-609.
36. Joffe RT. The use of thyroid supplements to augment antidepressant medication. J Clin Psychiatry 1998;59 (Suppl 5):26-29.
37. Prange AJ Jr. Novel uses of thyroid hormones in patients with affective disorders. Thyroid 1996;6:537-543.
38. Husain S, Kevan I, Linnell R, Scott A. Electroconvulsive treatment in depressive illness that has not responded to drug treatment. J Affect Disord 2004;83:121-126.
39. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 1990;31:287-296.
40. Loosen PT, Prange AJ Jr. Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: a review. Am J Psychiatry 1982;139:405-416.
41. Bauer M, London ED, Silverman DH, Rasgon N, Kirchheiner J, Whybrow PC. Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging. Pharmacopsychiatry 2003;3 (Suppl 3):215-221.
42. Joffe RT. Peripheral thyroid hormone levels in treatment resistant depression. Biol Psychiatry 1999;45:1053-1055.
43. Frye MA, Denicoff KD, Bryan AL, Smith-Jackson EE, Ali SO, Luckenbaugh D, et al. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry 1999;156:1909-1914.
44. Cole DP, Thase ME, Mallinger AG, Soares JC, Luther JF, Kupfer DJ, et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry 2002;159:116-121.
45. Whybrow PC, Prange AJ Jr. A hypothesis of thyroid-catecholamine- receptor interaction. Its relevance to affective illness. Arch Gen Psychiatry 1981;38:106-113.
46. Sullivan GM, Hatterer JA, Herbert J, Chen X, Roose SP, Attia E, et al. Low levels of transthyretin in the CSF of depressed patients. Am J Psychiatry 1999;156:710-715.
47. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001;158:1617-1622.
48. Goodwin FK, Prange AJ Jr, Post RM, Muscettola G, Lipton MA. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982;139:34-38.
49. Joffe RT, Bagby RM, Levitt AJ. The thyroid and melancholia. Psychiatry Res 1992;42:73-80.
50. Rabello MM, Snyder PJ, Utiger RD. Effects on the pituitary-thyroid axis and prolactin secretion of single and repetitive oral doses of TRH. J Clin Endocrinol Metab 1974;39:571-578.
51. Bowden CL, Lecrubier Y, Bauer M, Goodwin G, Greil W, Sachs G, et al. Maintenance therapies for classic and other forms of bipolar disorder. J Affect Disord 2000;59 (Suppl 1):57-67.
52. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47:435-440.
53. Stancer HC, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Arch Gen Psychiatry 1982;39:311-312.
54. Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial. Neuropsychopharmacology 1994; 10:183-189.
55. Baumgartner A, Dubeyko M, Campos-Barros A, Eravci M, Meinhold H. Subchronic administration of fluoxetine to rats affects triiodothyronine production and deiodination in regions of the cortex and in the limbic forebrain. Brain Res 1994;635: 68-74.
56. Hurowitz GI, Liebowitz MR. Antidepressant-induced rapid cycling: six case reports. J Clin Psychopharmacol 1993;13:52-56.
57. Bauer M, Hellweg R, Graf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998;18:444-455.
58. Joffe RT, Sokolov ST. Thyroid hormones, the brain and affective disorders. Crit Rev Neurobiol 1994;8:45-63.
59. Kornstein SG, Mcenany G. Enhancing pharmacologic effects in the treatment of depression in women. J Clin Psychiatry 2000; 61 (Suppl II):18-27.
60. Kohrle J. Thyroid hormone metabolism and action in the brain and pituitary. Acta Med Austriaca 2000;27:1-7.
61. Gyulai L, Bauer M, Garcia-Espana F, Hierholzer J, Baumgartner A, Berghofer A, et al. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord 2001;66: 185-191.
62. Gur E, Lerer B, Newman ME. Chronic chlomipramine and triiodothyronine increase 5 HT levels in rat frontal cortex in vivo: relationship to 5 HT autoreceptor activity. J Pharmacol Exp Ther 1999;288:81-87.
63. Dunn RT, Kimbrell TA, Ketter TA, Frye MA, Willis MW, Luckenbaugh DA, et al. Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. Biol Psychiatry 2002;51:387-399.